AXGN:NASDAQ
AxoGen, Inc Common Stock
US$ 50.64
arrow_upward
+1.24%(+0.62) Siku 1
US$ 50.64
0.00% (0.00)
bedtimeBaada ya saa
Imefungwa: 9 Nov, 16:00:00 GMT -5 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya AXGN...
Fungua
US$ 50.92
Juu
US$ 51.48
Chini
US$ 49.48
Mtaji wa soko
3.02B
Wastani wa kiasi cha mauzo
1.81M
Kiasi cha mauzo ya hisa
1.36M
Juu kwa wiki 52
US$ 52.91
Chini kwa wiki 52
US$ 23.00
EPS
-US$ 0.68
Beta
1.21
Hisa za wawekezaji
59.73M
Idadi ya wafanyakazi
622
Fungua
US$ 50.92
Juu
US$ 51.48
Chini
US$ 49.48
Mtaji wa soko
3.02B
Wastani wa kiasi cha mauzo
1.81M
Kiasi cha mauzo ya hisa
1.36M
Juu kwa wiki 52
US$ 52.91
Chini kwa wiki 52
US$ 23.00
EPS
-US$ 0.68
Beta
1.21
Hisa za wawekezaji
59.73M
Idadi ya wafanyakazi
622
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Yahoo Finance
·
saa 4 zilizopita
AXGN 8-K & SEC Filings
Investing.com Canada
·
saa 15 zilizopita
Form 8K Axogen Inc For: 9 November By Investing.com
Wasifu
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Kuhusu AxoGen, Inc Common Stock
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi622
Lilianzishwa2002
Makao makuuAlachua, Florida, Marekani
SektaHealth Care
Sekta-
Tovutiaxogeninc.com